Back to Search
Start Over
Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma
- Source :
- Journal of Clinical Oncology. 29:8012-8012
- Publication Year :
- 2011
- Publisher :
- American Society of Clinical Oncology (ASCO), 2011.
-
Abstract
- 8012 Background: LY2127399 (LY) is a human mAb that neutralizes membrane-bound and soluble B cell activating factor (BAFF). LY has activity in xenograft models of multiple myeloma (MM) and is being...
- Subjects :
- Cancer Research
biology
business.industry
medicine.drug_class
Bortezomib
Myeloma protein
Monoclonal antibody
medicine.disease
Phase i study
Oncology
immune system diseases
hemic and lymphatic diseases
Cancer research
biology.protein
Medicine
In patient
Antibody
business
B-cell activating factor
Multiple myeloma
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 29
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........cfca74fefb6c6f70968b50b7080559cd